Device Trial Radar · NCT06715345
Efficacy and Safety of Novosis Putty for Degenerative Lumbar Disease
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 6, 2024
Primary completion
Jul 8, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- CGBio Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study aims to evaluate the efficacy and safety of NOVOSIS PUTTY for bone fusion in patients requiring posterior instrumentation and transforaminal lumbar interbody fusion (TLIF) due to degenerative lumbar disease.
Conditions
- Degenerative Lumbar Diseases
Interventions
Bone graft materials and rhBMP-2Device
NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2(BMP2) and β-tricalcium phosphate/hydrogel complex.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall bone fusion rateTime frame: 12 months after surgery
- Overall fusion success rateTime frame: 12 months after surgery
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, South Korea
Asan medical center
Seoul, South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.